Organization Profile

You just read:

Oncothyreon Announces Merck Serono Decision to Continue the Development of Tecemotide in Stage III Non-Small Cell Lung Cancer

News provided by

Oncothyreon Inc.

Sep 25, 2013, 06:00 ET